MONTE ROSA THERAPEUTICS INC's ticker is GLUE and the CUSIP is 61225M102. A total of 70 filers reported holding MONTE ROSA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $345,386 | +210.8% | 92,349 | +485.8% | 0.00% | – |
| Q1 2024 | $111,136 | -47.1% | 15,764 | -57.6% | 0.00% | – |
| Q4 2023 | $210,056 | -19.1% | 37,178 | -31.4% | 0.00% | – |
| Q3 2023 | $259,666 | -16.4% | 54,210 | +19.6% | 0.00% | – |
| Q2 2023 | $310,552 | +23.7% | 45,336 | +40.7% | 0.00% | – |
| Q1 2023 | $251,095 | -24.9% | 32,233 | -26.7% | 0.00% | – |
| Q4 2022 | $334,551 | +122896.7% | 43,962 | +32.0% | 0.00% | – |
| Q3 2022 | $272 | -29.9% | 33,294 | -17.0% | 0.00% | – |
| Q2 2022 | $388 | -99.9% | 40,116 | -19.5% | 0.00% | – |
| Q1 2022 | $698,000 | -1.7% | 49,817 | +43.4% | 0.00% | – |
| Q4 2021 | $710,000 | +66.7% | 34,746 | +81.7% | 0.00% | – |
| Q3 2021 | $426,000 | -82.7% | 19,119 | -82.4% | 0.00% | -100.0% |
| Q2 2021 | $2,463,000 | – | 108,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,472,331 | $32,804,000 | 6.54% |
| Cormorant Asset Management, LP | 3,102,199 | $67,957,000 | 2.76% |
| NEA Management Company, LLC | 7,703,205 | $171,627,000 | 2.04% |
| Avoro Capital Advisors LLC | 3,311,434 | $61,003,000 | 0.96% |
| Octagon Capital Advisors LP | 150,000 | $3,342,000 | 0.82% |
| Alphabet Inc. | 1,464,015 | $32,618,000 | 0.77% |
| Casdin Capital, LLC | 960,883 | $21,408,000 | 0.53% |
| RTW INVESTMENTS, LP | 1,214,572 | $26,005,000 | 0.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 119,647 | $2,666,000 | 0.22% |
| Avidity Partners Management LP | 300,000 | $6,684,000 | 0.15% |